share_log

藥明康德:海外監管公告

WUXI APPTEC: Overseas Regulatory Notice

HKEX ·  Sep 11 05:27
Summary by Moomoo AI
药明康德於2024年9月10日召開董事會,通過以集中竞价交易方式回购A股股份的议案。該公司隨後於9月11日在上海證券交易所網站及指定媒體發布了回购報告書。在回购股份决议前一個交易日,即2024年9月10日,公司公布了前十大股东和前十大無限售条件股东的持股情況。其中,HKSCC NOMINEES LIMITED以13.29%的持股比例位居首位,持股類別為H股。該公告由董事長李革博士代表董事會發布。
药明康德於2024年9月10日召開董事會,通過以集中竞价交易方式回购A股股份的议案。該公司隨後於9月11日在上海證券交易所網站及指定媒體發布了回购報告書。在回购股份决议前一個交易日,即2024年9月10日,公司公布了前十大股东和前十大無限售条件股东的持股情況。其中,HKSCC NOMINEES LIMITED以13.29%的持股比例位居首位,持股類別為H股。該公告由董事長李革博士代表董事會發布。
WuXi AppTec held a board of directors meeting on September 10, 2024, and passed a proposal to repurchase A shares through centralized competitive trading. The company then published the repurchase report on the website of the Shanghai Stock Exchange and designated media on September 11. On the trading day prior to the repurchase resolution, i.e. on September 10, 2024, the company disclosed the shareholding situation of the top ten shareholders and the top ten unrestricted shareholders. Among them, HKSCC NOMINEES LIMITED ranked first with a shareholding proportion of 13.29%, with the share type listed in Hong Kong. The announcement was issued by Dr. Li Ge, Chairman of the Board of Directors, on behalf of the board of directors.
WuXi AppTec held a board of directors meeting on September 10, 2024, and passed a proposal to repurchase A shares through centralized competitive trading. The company then published the repurchase report on the website of the Shanghai Stock Exchange and designated media on September 11. On the trading day prior to the repurchase resolution, i.e. on September 10, 2024, the company disclosed the shareholding situation of the top ten shareholders and the top ten unrestricted shareholders. Among them, HKSCC NOMINEES LIMITED ranked first with a shareholding proportion of 13.29%, with the share type listed in Hong Kong. The announcement was issued by Dr. Li Ge, Chairman of the Board of Directors, on behalf of the board of directors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more